Suma Sri Chennapragada
Hematology & Oncology · Fort Smith, ARNPI 1831742154
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.2% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,415, more than ten times the $125 reported in 2022. That places this record below the midpoint for hematology & oncology clinicians in AR, where the typical reported total is $4,667.
Across 57 payments — averaging $28.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$260
- AbbVie$255
- Daiichi Sankyo Inc.$239
- Sanofi$132
- Tempus AI, Inc$112
- Novartis$84
- plus $549 from 15 others
What the payments were for
- Food & beverage$1,48891%
- Education$1439%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 6 | $260 |
| AbbVie | 9 | $255 |
| Daiichi Sankyo Inc. | 7 | $239 |
| Sanofi | 2 | $132 |
| Tempus AI, Inc | 2 | $112 |
| Novartis | 4 | $84 |
| GSK | 4 | $70 |
| Pfizer | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $56 |
| Johnson & Johnson | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Recordati_rare_diseases_inc. | 2 | $38 |
| Merck | 2 | $37 |
| Astellas Pharma US Inc | 2 | $32 |
| Geron Corporation | 1 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $27 |
| ADC Therapeutics America, Inc. | 1 | $26 |
| Syndax Pharmaceuticals, Inc. | 1 | $24 |
| Beone Medicines USA, Inc. | 1 | $19 |
| Bayer | 1 | $16 |
| Bristol Myers Squibb | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$125
How this compares
$1,632 in reported general payments places this provider in the 35th percentile of 92 hematology & oncology providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VenclextaVenetoclax | 13 | $129,588 |
| EliquisApixaban | 28 | $18,453 |
| Ondansetron OdtOndansetron | 25 | $1,142 |
| ValacyclovirValacyclovir Hcl | 16 | $616 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 37 | $605 |
| Oxycodone Hcl | 29 | $579 |
| Morphine Sulfate ErMorphine Sulfate | 23 | $520 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $310 |
| Anastrozole | 21 | $282 |
| Dexamethasone | 17 | $260 |
| Gabapentin | 24 | $254 |
| Pantoprazole Sodium | 22 | $198 |
| Potassium Chloride | 20 | $192 |
| Acyclovir | 12 | $77 |
| Prochlorperazine Maleate | 12 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVenclexta | $255 | $129,58813 claims |
| PfizerEliquis | $58 | $18,45328 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 92 hematology & oncology providers in Arkansas.
Other hematology & oncology in Fort Smith
- Isam Abdel-KarimFort Smith$199K
- Humdum DurraniFort Smith$54K
- Narender GorukantiFort Smith$20K
- Varant ArzoumanianFort Smith$7K
- Daniel MackeyFort Smith$6K
- Aswanth ReddyFort Smith$5K
- John WellsFort Smith$5K
- Daniel MilesFort Smith$2K
- Eric SchaeferFayetteville$466K
- Frits van RheeLittle Rock$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.